Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Piotr Rutkowski

Showing results (321-330 of 491) with videos related to

Pageof 50
Sort By:
European Journal of Cancer (Oxford, England : 1990)|April 17, 2018
Risk stratification of sentinel node-positive melanoma patients defines surgical management and adjuvant therapy treatment considerationsDaniëlle Verver, David van Klaveren, Alexander C J van Akkooi, et al.
BMC Cancer|January 17, 2016
Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trialPeter Reichardt, George D Demetri, Hans Gelderblom, et al.
Cancer|February 3, 2015
Clinical outcomes of patients with advanced gastrointestinal stromal tumors: safety and efficacy in a worldwide treatment-use trial of sunitinibPeter Reichardt, Yoon-Koo Kang, Piotr Rutkowski, et al.
Neurologia I Neurochirurgia Polska|January 15, 2025
Recommendations of Multiple Sclerosis and Neuroimmunology Section of Polish Neurological Society and Immuno-oncology Section of Polish Society of Oncology on oncological risk in patients with multiple sclerosis undergoing immunomodulatory therapyIwona Rościszewska-Żukowska, Alina Kułakowska, Alicja Kalinowska, et al.
Journal of Clinical Medicine|April 23, 2022
Long-Term Outcomes of Targeted Therapy after First-Line Immunotherapy in BRAF-Mutated Advanced Cutaneous Melanoma Patients-Real-World EvidencePaweł Rogala, Anna M Czarnecka, Bożena Cybulska-Stopa, et al.
Annals of Surgical Oncology|November 9, 2011
Patterns of care, prognosis, and survival in patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinibAntoine Italiano, Angela Cioffi, Paola Coco, et al.
Annals of Surgical Oncology|October 19, 2020
Has the Outcome for Patients Who Undergo Resection of Primary Retroperitoneal Sarcoma Changed Over Time? A Study of Time Trends During the Past 15 yearsDario Callegaro, Chandrajit P Raut, Deanna Ng, et al.
Cancers|January 21, 2022
Treatment of Locally Advanced Merkel Cell Carcinoma-A Multi-Center StudyMonika Dudzisz-Sledz, Paweł Sobczuk, Katarzyna Kozak, et al.
Cancer|January 10, 2018
Long-term outcome of dasatinib first-line treatment in gastrointestinal stromal tumor: A multicenter, 2-stage phase 2 trial (Swiss Group for Clinical Cancer Research 56/07)Michael Montemurro, Angela Cioffi, Julien Dômont, et al.
The Lancet. Oncology|October 27, 2018
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trialFrank Stephen Hodi, Vanna Chiarion-Sileni, Rene Gonzalez, et al.
Pageof 50

Showing results (321-330 of 491) with videos related to

Sort By:
Pageof 50
European Journal of Cancer (Oxford, England : 1990)|April 17, 2018
Risk stratification of sentinel node-positive melanoma patients defines surgical management and adjuvant therapy treatment considerationsDaniëlle Verver, David van Klaveren, Alexander C J van Akkooi, et al.
BMC Cancer|January 17, 2016
Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trialPeter Reichardt, George D Demetri, Hans Gelderblom, et al.
Cancer|February 3, 2015
Clinical outcomes of patients with advanced gastrointestinal stromal tumors: safety and efficacy in a worldwide treatment-use trial of sunitinibPeter Reichardt, Yoon-Koo Kang, Piotr Rutkowski, et al.
Neurologia I Neurochirurgia Polska|January 15, 2025
Recommendations of Multiple Sclerosis and Neuroimmunology Section of Polish Neurological Society and Immuno-oncology Section of Polish Society of Oncology on oncological risk in patients with multiple sclerosis undergoing immunomodulatory therapyIwona Rościszewska-Żukowska, Alina Kułakowska, Alicja Kalinowska, et al.
Journal of Clinical Medicine|April 23, 2022
Long-Term Outcomes of Targeted Therapy after First-Line Immunotherapy in BRAF-Mutated Advanced Cutaneous Melanoma Patients-Real-World EvidencePaweł Rogala, Anna M Czarnecka, Bożena Cybulska-Stopa, et al.
Annals of Surgical Oncology|November 9, 2011
Patterns of care, prognosis, and survival in patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinibAntoine Italiano, Angela Cioffi, Paola Coco, et al.
Annals of Surgical Oncology|October 19, 2020
Has the Outcome for Patients Who Undergo Resection of Primary Retroperitoneal Sarcoma Changed Over Time? A Study of Time Trends During the Past 15 yearsDario Callegaro, Chandrajit P Raut, Deanna Ng, et al.
Cancers|January 21, 2022
Treatment of Locally Advanced Merkel Cell Carcinoma-A Multi-Center StudyMonika Dudzisz-Sledz, Paweł Sobczuk, Katarzyna Kozak, et al.
Cancer|January 10, 2018
Long-term outcome of dasatinib first-line treatment in gastrointestinal stromal tumor: A multicenter, 2-stage phase 2 trial (Swiss Group for Clinical Cancer Research 56/07)Michael Montemurro, Angela Cioffi, Julien Dômont, et al.
The Lancet. Oncology|October 27, 2018
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trialFrank Stephen Hodi, Vanna Chiarion-Sileni, Rene Gonzalez, et al.
Pageof 50